Insmed Inc (INSM)vsSyndax Pharmaceuticals Inc (SNDX)
INSM
Insmed Inc
$148.31
+6.59%
HEALTHCARE · Cap: $29.99B
SNDX
Syndax Pharmaceuticals Inc
$24.20
+0.75%
HEALTHCARE · Cap: $2.13B
Smart Verdict
WallStSmart Research — data-driven comparison
Insmed Inc generates 252% more annual revenue ($606.42M vs $172.35M). INSM leads profitability with a -2.1% profit margin vs -165.6%. INSM earns a higher WallStSmart Score of 39/100 (F).
INSM
Hold39
out of 100
Grade: F
SNDX
Avoid30
out of 100
Grade: F
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
No standout strengths identified
Revenue surging 795.0% year-over-year
Areas to Watch
1.5% revenue growth
0.0% earnings growth
Trading at 43.0x book value
ROE of -2.5% — below average capital efficiency
0.0% earnings growth
Trading at 32.7x book value
ROE of -161.8% — below average capital efficiency
Negative free cash flow — burning cash
Comparative Analysis Report
WallStSmart ResearchBull Case : INSM
PEG of 1.09 suggests the stock is reasonably priced for its growth.
Bull Case : SNDX
The strongest argument for SNDX centers on Revenue Growth. Revenue growth of 795.0% demonstrates continued momentum.
Bear Case : INSM
The primary concerns for INSM are Revenue Growth, EPS Growth, Price/Book.
Bear Case : SNDX
The primary concerns for SNDX are EPS Growth, Price/Book, Return on Equity.
Key Dynamics to Monitor
INSM profiles as a turnaround stock while SNDX is a hypergrowth play — different risk/reward profiles.
INSM carries more volatility with a beta of 1.17 — expect wider price swings.
SNDX is growing revenue faster at 795.0% — sustainability is the question.
SNDX generates stronger free cash flow (-70M), providing more financial flexibility.
Bottom Line
INSM scores higher overall (39/100 vs 30/100). Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Insmed Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Insmed Incorporated, a biopharmaceutical company, develops and markets therapies for patients with rare and serious diseases. The company is headquartered in Bridgewater, New Jersey.
Syndax Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. The company is headquartered in Waltham, Massachusetts.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?